All In Biotech

Drug Trial Radar · NCT07190885

A Pharmacokinetic Study of YN001 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

24

Planned (sponsor's estimate)

Start

Nov 18, 2025

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Sponsor type
Industry
First posted
Sep 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, single-center, open-label study designed to evaluate the pharmacokinetics (PK), safety, and immunogenicity following a single dose administration in healthy adult volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • YN001Drug

    YN001 administered via intravenous infusion. Participants will receive either 20 mg (Cohort 1) or 40 mg (Cohort 2).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the maximum plasma concentration (Cmax) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
  2. To evaluate the time to reach maximum plasma concentration (Tmax) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
  3. To evaluate the area under the concentration-time curve from time 0 to last measurable concentration (AUC0-t) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
  4. To evaluate the area under the concentration-time curve extrapolated to infinity (AUCinf) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
  5. To evaluate the terminal elimination rate constant (λz) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
  6. To evaluate the plasma half-life (T1/2) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
  7. To evaluate the clearance (CL) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).
  8. To evaluate the volume of distribution (Vd) of YN001Time frame: From pre-dose (Day 1) through 120 hours post-dose (Day 6).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.